OncoMatch/Lymphoma — Diffuse Large B-Cell (DLBCL)/BCL6 rearrangement
Lymphoma — Diffuse Large B-Cell (DLBCL)BCL6 rearrangement Clinical Trials
BCL6 rearrangements are present in approximately 30% of DLBCL and contribute to germinal center B-cell (GCB) subtype biology and transcriptional reprogramming. Triple-hit lymphoma (MYC + BCL2 + BCL6) carries the worst prognosis among rearranged DLBCL subtypes. Trials investigate BCL6 degraders and inhibitors including BI-3802 and compound library approaches, alongside combination regimens for BCL6-rearranged DLBCL.
Top recruiting BCL6 rearrangement Lymphoma — Diffuse Large B-Cell (DLBCL) trials
Ranked by phase and US site count.
See all trials matched to your profile →Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
More BCL6 rearrangement Lymphoma — Diffuse Large B-Cell (DLBCL) trials
2 international trials (no US sites)
Browse other molecular targets with active Lymphoma — Diffuse Large B-Cell (DLBCL) trials.